Harmony Biosciences appoints Dr. Jeffrey M. Dayno as new CEO

Byline optimized for SEO: Harmony Biosciences appoints Dr. Jeffrey M. Dayno as new President and CEO; previously Interim President and CMO

Leadership Changes

April 24, 2023

Harmony Biosciences, a pharmaceutical company specializing in treatments for rare neurological diseases, has announced the appointment of Dr. Jeffrey M. Dayno as the new President and CEO. Dr. Dayno has been serving as the Interim President and CEO since January 2023, and he was previously the Chief Medical Officer and Executive Vice President since the company's founding in 2017.

Dr. Dayno brings extensive industry experience to the role, having spent 25 years in the industry after 12 years as a practicing neurologist. He played a crucial role in obtaining FDA approval for the company's key asset, WAKIX (pitolisant), and helped shape the company's commercial strategy.

Board Chairman Jeff Aronin notes Dr. Dayno's influence

Harmony's Board Chairman, Jeff Aronin, praised Dr. Dayno's leadership, stating that he has been an influential leader since the company's founding. Mr. Aronin also noted that the Board unanimously appointed Dr. Dayno as CEO due to their belief in his vision for ongoing strong growth in critical areas of the business. He expects that Dr. Dayno will continue to expand the WAKIX franchise in narcolepsy, pursue new indications for patients, and advance the pipeline of new assets.

Dr. Dayno expresses gratitude for the Board's confidence

In response to his appointment, Dr. Dayno expressed his appreciation for the Board's confidence in his leadership. He highlighted his passion for developing and delivering innovative treatments that can have a significant impact on patients and their families. He believes that WAKIX has the potential to be a billion-dollar-plus narcolepsy opportunity and could contribute up to an additional billion dollars if approved in idiopathic hypersomnia and other current lifecycle management programs.

Mr. Aronin returns to serving as non-executive Chairman of the Board

With Dr. Dayno's appointment, Mr. Aronin will return to serving as non-executive Chairman of the Board. The Board is confident that Dr. Dayno's leadership will help the company achieve its goals and create both short- and long-term value for Harmony's shareholders.

Members of LevelFields received the alert of this event on April 24, 8:25 AM ET

Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions,and let LevelFields help you become a better trader.

Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.

Free Trial: Signup for 1 Free Alert Per Week

Add your email to get alerts & the report.

Get 1 free alert per week via email

Upgrade if you want more or platform access

We'll also send you a free report

or Click Here to get full access now

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.